Zhao Jian-Guo, Hu Ya, Liao Quan, Niu Zhe-Yu, Zhao Yu-Pei
Jian-Guo Zhao, Ya Hu, Quan Liao, Zhe-Yu Niu, Yu-Pei Zhao, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
World J Gastroenterol. 2014 May 21;20(19):5875-80. doi: 10.3748/wjg.v20.i19.5875.
To investigate the prognostic significance of pretreatment standardized maximum uptake value (SUVmax) and serum carbohydrate antigen (CA)19-9 in pancreatic cancer.
From January 2007 to October 2011, 80 consecutive patients with pancreatic cancer who received positron emission/computed tomography before any treatment were enrolled in this study. The pretreatment SUVmax and CA19-9 level of the primary pancreatic tumor were obtained and compared with clinicopathological and prognostic factors. Student's t test for unpaired data was used to analyze the differences between two groups. Univariate analysis and Cox proportional hazards regression were used to examine the independent effects of each significant variable. Survival was analyzed by the Kaplan-Meier method.
There was a significant correlation between both the SUVmax and serum CA19-9 of pancreatic cancer and R0 surgical resection (P = 0.043 and P = 0.007). Lymph node metastasis was associated with SUVmax (P = 0.017), but not serum CA19-9 (P = 0.172). On the contrary, the tumor stage was significantly related to serum CA19-9 (P = 0.035), but not SUVmax (P = 0.110). The univariate analysis showed that survival time was significantly related to tumor stage (P < 0.001), lymph node metastasis (P = 0.043), R0 surgical resection (P < 0.001), serum CA19-9 (P = 0.001), SUVmax (P < 0.001) and SUVmax plus CA19-9 (P = 0.002). Multivariate analysis clearly showed that only tumor stage (hazard ratio = 0.452; P = 0.020) was an independent prognostic factor for overall survival in pancreatic cancer. Higher SUVmax or CA19-9 showed worse prognosis. We found that high serum CA19-9 plus SUVmax was the most significant variable.
Higher pretreatment SUVmax and serum CA19-9 indicates poor prognosis. SUVmax plus serum CA19-9 is the most significant variable in predicting survival.
探讨胰腺癌治疗前标准化最大摄取值(SUVmax)及血清糖类抗原(CA)19-9的预后意义。
2007年1月至2011年10月,80例未经任何治疗即接受正电子发射断层扫描/计算机断层扫描的连续性胰腺癌患者纳入本研究。获取原发性胰腺肿瘤的治疗前SUVmax及CA19-9水平,并与临床病理及预后因素进行比较。采用非配对数据的学生t检验分析两组间差异。采用单因素分析及Cox比例风险回归分析各显著变量的独立作用。采用Kaplan-Meier法分析生存情况。
胰腺癌的SUVmax及血清CA19-9与R0手术切除均显著相关(P = 0.043及P = 0.007)。淋巴结转移与SUVmax相关(P = 0.017),但与血清CA19-9无关(P = 0.172)。相反,肿瘤分期与血清CA19-9显著相关(P = 0.035),但与SUVmax无关(P = 0.110)。单因素分析显示,生存时间与肿瘤分期(P < 0.001)、淋巴结转移(P = 0.043)、R0手术切除(P < 0.001)、血清CA19-9(P = 0.001)、SUVmax(P < 0.001)及SUVmax加CA19-9(P = 0.002)显著相关。多因素分析明确显示,仅肿瘤分期(风险比 = 0.452;P = 0.020)是胰腺癌总体生存的独立预后因素。较高的SUVmax或CA19-9提示预后较差。我们发现高血清CA19-9加SUVmax是最显著的变量。
较高的治疗前SUVmax及血清CA19-预后较差。SUVmax加血清CA19-9是预测生存的最显著变量。